Personalized mRNA vaccine shows lasting benefits for high-risk melanoma patients

euronews.com

A personalized mRNA vaccine combined with immunotherapy shows lasting benefits for high-risk melanoma patients. The experimental therapy reduced the risk of cancer recurrence or death by 49% compared to immunotherapy alone in a phase 2 trial. This approach trains the immune system to fight cancer, with phase 3 trials underway for melanoma and other cancers.


With a significance score of 6.3, this news ranks in the top 0.1% of today's 31590 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: